1. Rezaee SA, Fazly Bazzaz BS. The significance of HTLV-I in molecular oncology. Iran J Basic Med Sci 2013; 3:178.
2. Rafatpanah H, Rezaee A, Etemadi M, Farid Hossseini R, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1 associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
3. Franchini G. Molecular mechanisms of humanT-cell leukemia/ lymphotropic virus type I infection. Blood 1995; 86:3619–3639.
4. Vakili R, Sabet F, Ahmadi Ghezeldasht S, Boostani R, Rafatpanah H, Shamsian A, et al. Human T-lymphotropic virus type I (HTLV-I) proviral load and clinical features in Iranian HAM/TSP patients. Iran J Basic Med Sci 2013; 16:268-272.
5. Yakova M, Lezin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005; 2:4.
6. Manns A, Hisada M, LaGrenade L. HumanT-lymphotropicvirus type I infection. Lancet 1999; 353:1951–1958.
7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R, Bazarbachi A. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011 Nov; 52:172-176.
8. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 T cells, and disease severity in− HTLV-1 associated myelopathy (HAM/TSP) . blood 2002; 99:88 94.
9. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-associated leukemo genesis in vivo. Leukemia 2003; 17:26–38.
10. Jacobson S, Zaninovic V, Mora C, Rodgers-Johnson P, Sheremata WA, Gibbs CJ Jr, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23:S196–200.
11. Jacobson S, Gupta A, Mattson D, Mingioli E, Mc-Farlin DE. Immunological studies intropical spastic paraparesis. Ann Neurol 19990; 27:149-156.
12. Nyborg JK, Dynan WS. Interaction of cellular proteins with the human Tcell leukemi a virus type I transcriptional control region. Purification of cellular proteins that bind the 21-base pair repeat elements. J Biol Chem 1990; 265:8230–8236.
13. Masuda ES, Imamura R, Amasaki Y, Arai,and K, Arai N. Signalling in to the T-cell nucleus: NFAT regulation. Cell Signal 1998; 10:599–611.
14. Hatanaka M, Kobayashi N. The pX region of HTLV-I. Princess Takamatsu Symp 1984; 15:205-217.
15. Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci 2004; 9:2556-2576.
16. Pique C, Dokhelar MC. In vivo production of proteins of HTLV type1: evidence from cytotoxic Tlymphocytes. AIDS Res Hum Retroviruses 2000; 16:1783–1786.
17. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneousT-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415–7419.
18. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, et al. Quantitative proviral DNA and antibody levels in the natural History of HTLV-1 infection. J Infect Dis 1999; 180:1487-1493.
19. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers:high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593.
20. Iwanaga M, Watanabe T, Utsunomiya T, Okayama M, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116:1211-1219.
21. Goncalves DU, Proietti FA, Barbosa Stancioli EF, Martins ML, Ribas JG, Martins Filho OA, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008; 7:98-107
22. Izumo S. Neuropathology of HTLV-1-associated myelopathy (HAM/TSP). Neuropathology 2010; 30:480.
23. Rios Grassi MF, Olavarria VN, Kruschewsky RdA, Mascarenhas RE, Dourado I, Correia LCL, et al. Human T Cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83:1269-1274.
24. Matsuura E, Yamano Y, Jacobson S. Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol 2010; 5:310-325.
25. Miyoshi I, Kubonishi I,Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. TypeC virus particles in acord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic Tcells. Nature 1981; 294:770-771.
26. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of typeC retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-7419.
27. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004; 37:112-114, 116,118-119.
28. Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, et al. Quantification of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002; 102:37-51.
29. Kalavi Kh, Moradi A, Tabarraei A. Population based sero prevalence of HTLV-I infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci 2013; 16:225-228.
30. Lin HC, Dezzutti CS, Lal RB, Rabson AB. Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells. J Virol 1998; 72:6264–6270.
31. Lin HC, Hickey M, Hsu L, Medina D, Rabson AB.
Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology 2005; 339:1–11.
32. Lin HC, Charlene S, Dezzutti, Renu B. Lal,A, Rabson AB. Activation of Human T-Cell leukemia virus type 1 tax gene expression in chronically infected T Cells. J Virol 1998; 7:6264–6270.
33. Furukawa Y, Saito M, Matsumoto W, Usuku K, Tanaka Y, Izumo S, et al. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)–associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers. J Infect Dis 2003; 187:1116–1125.
34. Best I, Adaui V, Verdonck K, González E, Tipismana M, Clark D, et al. 2Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 2006; 146:226–233.
35. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003; 308:1-12.
36. Bangham CR, Hall SE, Jeffery KJ, Vine AM, Witkover A, Nowak MA, et al. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci 1999; 354:691- 700.
37. Akagi T, Ono H, Nyunoya H, Shimotohno K. Characterization of peripheral blood T-lymphocytes transduced with HTLV-1 Tax mutants with different trans-activating phenotype. Oncogene 1997; 14:2071–2078.
38. Grassmann R, Dengler C, Muller-Fleckenstein I, Fleckenstein B, McGuire K, Dokhelar MC, Sodroski JG, Haseltine WA. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a herpesvirus saimiri vector. Proc Natl Acad Sci USA 1989; 86:3351–3355.